A crossover study involving multiple cancer types demonstrated that tumors with higher TMB exhibited better responses to PD-1/PD-L1 therapy, and there was a positive correlation between TMB and PD-L1 expression on tumor cells (Yarchoan et al., 2017). The gene discussed is CD274; the disease is neoplasm.